Pilot-study into the effectiveness of neurofeedback in the treatment of major depressive disorder (MDD).

Pilot-study into the effectiveness of neurofeedback in the treatment of major depressive disorder.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26159

Enrollment

Registered

2009-01-14

Start date

2009-04-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder, depression

Interventions

Neurofeedback will be administered based by means of frontal alpha-asymmetry (FA) feedback. Baseline resting-EEG signal will be analyzed and individual thresholds will be used to provide real-time vi

Eligibility

Inclusion criteria

Inclusion criteria: 1. MMD as a primary axis-1 diagnosis according to criteria of the DSM-IV-TR; 2. Informed consent.

Exclusion criteria

Exclusion criteria: 1. History of braintrauma (commotio or contusio cerebri); 2. Current use of antipsychotics, moodstabilizers, benzodiazepines. the use of antidepressants is permitted if type and dosage are not changed during participation in the study; 3. Chronic MDD (>2 years duration of current episode); 4. Dysthymia; 5. Bipolar disorder; 6. Lefthandedness; 7. Severe (HDRS-17 > 25) episode of MDD which indicates prompt effective treatment; 8. Pregnancy; 9. Other psychiatric disorders other than co-morbid anxiety and personality disorders.

Design outcomes

Primary

Measure	Time frame
1. Hamilton depression rating scale (17-item); 2. Baseline frontal alpha-activity in resting EEG.	—

Secondary

Measure	Time frame
Quick Inventory Depression Scale- SelfRating (16 items).	—

Contacts

Public ContactF.P.M.L. Peeters

Department of Psychiatry University Hospital Maastricht P.O. Box 5800

f.peeters@maastrichtuniversity.nl043-3874130

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)